Get the Stockscreener App
1.18
0.84%
-0.01
After Hours:
1.18
Accelerate Diagnostics Inc stock is traded at $1.18, with a volume of 24,932.
It is down -0.84% in the last 24 hours and up +0.85% over the past month.
Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.
See More
Previous Close:
$1.19
Open:
$1.21
24h Volume:
24,932
Relative Volume:
0.46
Market Cap:
$29.55M
Revenue:
$12.00M
Net Income/Loss:
$-63.23M
P/E Ratio:
-0.1967
EPS:
-6
Net Cash Flow:
$-43.02M
1W Performance:
+0.00%
1M Performance:
+0.85%
6M Performance:
-33.71%
1Y Performance:
+21.65%
1-Day Range:
$1.14
$1.2155
1-Week Range:
$1.07
$1.235
52-Week Range:
$0.73
$2.09
Accelerate Diagnostics Inc Stock (AXDX) Company Profile
Name
Accelerate Diagnostics Inc
Sector
Industry
Phone
303-863-8088
Address
3950 S. COUNTRY CLUB ROAD #470, TUCSON, AZ
Compare AXDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AXDX
Accelerate Diagnostics Inc
|
1.18 | 29.55M | 12.00M | -63.23M | -43.02M | -6.00 |
|
ABT
Abbott Laboratories
|
134.95 | 234.06B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
104.39 | 154.06B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
387.92 | 148.02B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
90.17 | 115.71B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
72.76 | 42.91B | 5.72B | 4.17B | 490.10M | 6.97 |
Accelerate Diagnostics Inc Stock (AXDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-09-22 | Downgrade | Craig Hallum | Buy → Hold |
| Oct-08-20 | Initiated | BTIG Research | Neutral |
| Aug-07-20 | Upgrade | Craig Hallum | Hold → Buy |
| Sep-27-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-07-18 | Downgrade | JP Morgan | Overweight → Neutral |
| May-24-18 | Initiated | Craig Hallum | Hold |
| Dec-13-17 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-12-17 | Resumed | BTIG Research | Buy |
| Mar-24-16 | Initiated | JP Morgan | Overweight |
| Dec-16-15 | Initiated | Piper Jaffray | Overweight |
View All
Accelerate Diagnostics Inc Stock (AXDX) Latest News
Accelerate Diagnostics (NASDAQ:AXDX) Coverage Initiated at StockNews.com - Defense World
StockNews.com Begins Coverage on Accelerate Diagnostics (NASDAQ:AXDX) - Defense World
Accelerate Diagnostics, Inc. to Host Earnings Call - ACCESS Newswire
Accelerate Diagnostics (NASDAQ:AXDX) Research Coverage Started at StockNews.com - Armenian Reporter
Axos Invest Inc. Purchases 54,293 Shares of Vanguard FTSE Developed Markets ETF (NYSEARCA:VEA) - Armenian Reporter
Antimicrobial Susceptibility Testing Market Advancements Highlighted by Analysis and Forecast to 2033: Mark... - WhaTech
Indaba Capital Management, L.P. Acquires Significant Stake in Ac - GuruFocus.com
BD to separate biosciences and diagnostics business - BioWorld Online
Methicillin-Resistant Staphylococcus Aureus (MRSA) Testing Market Projected to Reach USD 6.5 Billion by 2035 at a 4.2% of CAGR | Future Market Insights, Inc. - Morningstar
Global Antimicrobial Resistance Surveillance Market to Reach USD 9.50 Billion by 2032, Growing at a CAGR of 5.47% - WICZ
Accelerate Diagnostics faces Nasdaq delisting risk By Investing.com - Investing.com South Africa
Accelerate Diagnostics faces Nasdaq delisting risk - Investing.com
Global Antimicrobial Susceptibility Testing Market to Reach USD 4.8 Billion by 2035, Growing at a CAGR of 3.6% | Future Market Insights, Inc. - GlobeNewswire Inc.
Accelerate Diagnostics (NASDAQ:AXDX) Share Price Passes Below 200-Day Moving Average – Time to Sell? - Defense World
Accelerate Diagnostics (NASDAQ:AXDX) Now Covered by Analysts at StockNews.com - Defense World
StockNews.com Initiates Coverage on Accelerate Diagnostics (NASDAQ:AXDX) - Defense World
Accelerate Diagnostics reports preliminary FY 2024 revenue of $11.7 million - MSN
Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results - PR Newswire
Cofactor Genomics, Inc. Announces CEO Transition in Preparation for Accelerated Commercial Growth and Increased Patient Access for OncoPrism, its Medicare Approved Immunotherapy Test - Business Wire
GRIFFIN ASSET MANAGEMENT, INC. Reduces Holdings in Accelerate Di - GuruFocus.com
Aptitude Secures $10M+ to Accelerate Development of Point-of-Care and Over-the-Counter CT/NG/TV STI Test on Metrix® Platform - PR Newswire
Accelerate Diagnostics (NASDAQ:AXDX) Coverage Initiated by Analysts at StockNews.com - Defense World
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Short Interest Update - Defense World
Accelerate Diagnostics (AXDX) – Investment Analysts’ Weekly Ratings Changes - Defense World
Accelerate Diagnostics (NASDAQ:AXDX) Earns Hold Rating from Analysts at StockNews.com - Defense World
Antimicrobial Susceptibility Testing Market Outlook & Trends 2024: Global Forecast & Insights - WhaTech
Antimicrobial Susceptibility Testing Market Analysis - openPR
T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens - Yahoo Finance
ACEL Stock Hits 52-Week High at $12.62 Amid Market Optimism - Investing.com UK
ACEL Stock Hits 52-Week High at $12.62 Amid Market Optimism By Investing.com - Investing.com South Africa
Accelerate Diagnostics director John Patience buys $314k in common stock - Investing.com Nigeria
Accelerate Diagnostics director Jack Schuler sells $314,000 in stock By Investing.com - Investing.com Nigeria
Accelerate Diagnostics director Jack Schuler sells $314,000 in stock - Investing.com India
Accelerate Diagnostics (NASDAQ:AXDX) Raised to “Hold” at StockNews.com - Defense World
Glox Therapeutics awarded grant to accelerate development of precision antibiotics - European Pharmaceutical Manufacturer
Microbial Identification Market Size, Trends, Latest Insights, Analysis and Forecast 2024-2031 - WhaTech
Sepsis Diagnostics Market To Grow at 8.5% By 2032Market.us Media - Market.us Media - United States Market News
Armistice Capital, LLC's Strategic Acquisition in Accelerate Dia - GuruFocus.com
William Blair Has Bearish Estimate for AXDX FY2024 Earnings - Defense World
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q3 2024 Earnings Call Transcript - Insider Monkey
GE HealthCare and RadNet Forge Collaboration to Transform Imaging Systems and Accelerate the Adoption of Artificial Intelligence (AI) with SmartTechnology - BioSpace
Next-generation rapid phenotypic antimicrobial susceptibility testing - Nature.com
Accelerate Diagnostics (AXDX) Reports Q3 Loss, Lags Revenue Estimates - MSN
Accelerate Diagnostics: Q3 Earnings Snapshot - Houston Chronicle
Accelerate Diagnostics Reports Key Advances Amid Financial Challenges - TipRanks
Accelerate Diagnostics Inc Stock (AXDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):